# BPC-157 TB-500 Dosage: Animal-Study Ranges, Routes, and Half-Life

> BPC-157 TB-500 dosage in the literature is component-level and preclinical: rat 10 microg/kg BPC-157, wide-range Thymosin Beta-4, and no validated blend dose. Research context, not human guidance. Cited.

There is no validated dose for the blend. The figures here are the doses administered to specific species in specific studies — research context, never a human protocol.

## BPC-157 TB-500 dosage in the preclinical record

BPC-157 TB-500 dosage, in the published record, exists only at the level of the individual constituents and only in animal and biochemical studies. There is no validated dose for the blend, and the figures below are reported as "studied at X in [species]," never as a recommendation for human use [11].

### What doses of BPC-157 and TB-500 have been studied (in animals)?

BPC-157 component (animal models). Rodent studies commonly express dose per body weight; the transected-Achilles-tendon work used 10 microg/kg or 10 ng/kg [1], and gastric-ulcer cytoprotection has been studied in rats at roughly 400-800 ng/kg [11]. TB-500 / Thymosin Beta-4 component (animal models). The range is wide and the schedules differ by model: a rat embolic-stroke dose-response study spanned 2-18 mg/kg intraperitoneal, with an optimal modeled near 3.75 mg/kg and 18 mg/kg giving no benefit [4], and an mdx muscular-dystrophy study used 150 microg twice weekly for six months [4]. The blend itself has no validated dose [11].

Commercial research-product labeling commonly pairs BPC-157 and TB-500 at fixed combined masses per vial — for example, roughly 10 mg plus 10 mg, or a 20 mg combined vial — but no peer-reviewed combination dose-finding study exists, so no ratio or dose for the assembled blend has been validated [3][11].

The only human single-agent reference points belong to full-length Thymosin Beta-4, not the TB-500 heptapeptide and not the blend: intravenous Thymosin Beta-4 was reported well tolerated up to high single doses in early Phase 1 work, and a first-in-human study used low microgram-per-kilogram doses over a short course [11]. Those figures describe a different molecule administered in a controlled trial, and they do not translate into a dose for either the fragment or the two-peptide preparation. The honest reading is that the marketed blend's quantitative profile rests on animal data for its two specimens and on parent-protein data for one of them [4][11].

## Routes studied in the component literature

### The 'wolverine injection' framing, in research terms

The "wolverine injection" framing common online maps onto routes studied in animals, not validated human-use instructions. The predominant routes in the rodent efficacy studies for both peptides are intraperitoneal; subcutaneous and intramuscular are the predominant research-community routes for the blend, though not from controlled human efficacy trials [11]. Intravenous appears in the human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 IV safety pilot, and local, intra-lesional, and topical routes appear in individual-compound wound and tendon models [11]. None of these is a human-use instruction.

### Is bpc 157 tb 500 oral administration validated?

The phrase bpc 157 tb 500 oral follows from BPC-157 being studied as a "stable gastric" peptide, which is the basis for interest in oral administration [11]. But marketed oral blend products lack validated pharmacokinetics: there is no established oral PK for the assembled BPC-157 plus TB-500 blend, and the parenteral routes above dominate the efficacy literature for both constituents [11]. Oral interest is a property of one component, not a validated delivery route for the pair.

## Half-life, reconstitution, frequency, and cycling

### What is the half-life of BPC-157 and TB-500?

BPC-157's elimination half-life was reported under 30 minutes in animal PK studies [11]; no validated half-life is established for the TB-500 fragment, and none for the blend. Human IV full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics, but no specific half-life is established for the Ac-LKKTETQ heptapeptide [11].

### How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [11]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [3]. No human-use reconstitution instructions apply to a research chemical.

### How often should you inject BPC-157 and TB-500?

There is no validated dosing schedule for the blend. The underlying animal studies use widely differing schedules — for example, Thymosin Beta-4 at 150 microg twice weekly for six months in one mouse study [4] — and community "loading then maintenance" protocols have no controlled-trial basis and should not be presented as validated dosing [11].

### How do you cycle BPC-157 and TB-500?

No controlled trial defines a cycle for the blend. Community "loading then maintenance" schedules and fixed-ratio vials have no validated basis, and a rat dose-response study found Thymosin Beta-4 effects non-monotonic — 18 mg/kg gave no benefit, so higher was not better [4]. Component animal studies use widely differing schedules by species and route [11].

---

Two peptides set on one studio table and shown straight — BPC-157 and TB-500 lit specimen by specimen, the Thymosin Beta-4 tumor signal and the 503A status left in plain view, with no clinic behind the lens and nothing here dispensed.